Next-generation multiplex-edited CAR-NK cells: more edits, more power?
Journal for ImmunoTherapy of Cancer · 2025-09 · 13 (9) · e012841
DOI: 10.1136/jitc-2025-012841 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 15.09.2025. Verfasst von Tobias Bexte und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Experimental Immunology and Celltherapy, Goethe University Frankfurt, Frankfurt am Main, Germany bexte@med.uni-frankfurt.de. Hauptthemen laut MEDLINE: Killer Cells, Natural, Gene Editing, Receptors, Chimeric Antigen, Immunotherapy, Adoptive. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
First clinical trials demonstrated the safety of adoptive cell transfer with allogeneic natural killer (NK) cell products from healthy donors, making them an attractive candidate for ‘off-the-shelf’ chimeric antigen receptor (CAR)-immune cell therapy. However, reduced persistence and inactivation of NK cells by immunosuppressive cues likely limit the performance of CAR-redirected NK cells. Wang and colleagues demonstrate that multiplex CRISPR base editing allows optimization of the intrinsic functionality of CAR-NK cells improving their therapeutic potential. In contrast to conventional CRISPR-Cas nucleases, base editing avoided most double-stranded DNA breaks while enabling highly efficient editing at up to six sites simultaneously. The study further demonstrates the feasibility of a non-viral approach to integrate CAR transgene and multiplex base editing of several immune checkpoints in NK cells using a single electroporation. CAR-NK cells harboring up to three base edits demonstrate improved potency over unedited counterparts in vitro. Xenograft mouse models confirmed increased potency, but also indicated signs of organ toxicity - a phenomenon that will require future studies prior to clinical translation. The study demonstrates that CRISPR base editing is a powerful tool to unleash the full cytotoxic potential of NK cells, but it also warrants the question: How many internal breaks can be removed without hurting CAR-NK cell therapy’s impeccable safety record?
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Experimental Immunology and Celltherapy, Goethe University Frankfurt, Frankfurt am Main, Germany bexte@med.uni-frankfurt.de.
- Institute for Transfusion Medicine and Immunohematology, German Red Cross Hesse, Frankfurt am Main, HE, Germany.
- Berlin Center for Advanced Therapies, Charité - Universitätsmedizin Berlin, Berlin, BE, Germany.
- Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA.
- Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, USA.
- Berlin Institute of Health Center for Regenerative Therapies, Berlin Institute of Health at Charité, Berlin, BE, Germany.
Zitieren
APA
Bexte, T., & Wagner, D. L. (2025). Next-generation multiplex-edited CAR-NK cells: more edits, more power?. Journal for ImmunoTherapy of Cancer, 13(9), e012841. https://doi.org/10.1136/jitc-2025-012841
Vancouver
Bexte T, Wagner DL. Next-generation multiplex-edited CAR-NK cells: more edits, more power?. Journal for ImmunoTherapy of Cancer. 2025;13(9):e012841. doi:10.1136/jitc-2025-012841
BibTeX
@article{Bexte2025,
author = {Bexte, Tobias and Wagner, Dimitrios L},
title = {Next-generation multiplex-edited CAR-NK cells: more edits, more power?},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2025},
volume = {13},
number = {9},
pages = {e012841},
doi = {10.1136/jitc-2025-012841}
}
EUVIMED